Scarica l'app Stockscreener
34.36
5.85%
1.90
Dopo l'orario di chiusura:
34.56
0.20
+0.58%
Precedente Chiudi:
$32.46
Aprire:
$32.97
Volume 24 ore:
339.90K
Relative Volume:
0.93
Capitalizzazione di mercato:
$2.38B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+4.76%
1M Prestazione:
+12.69%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$32.80
$34.62
Intervallo di 1 settimana:
$31.94
$35.28
Portata 52W:
$18.84
$38.54
Alamar Biosciences Inc Stock (ALMR) Company Profile
Nome
Alamar Biosciences Inc
Settore
Industria
Telefono
510-626-9888
Indirizzo
47071 BAYSIDE PARKWAY, FREMONT
Compare ALMR vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALMR
Alamar Biosciences Inc
|
34.36 | 2.28B | 0 | 0 | 0 | 0.00 |
ABT
Abbott Laboratories
|
97.50 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Alamar Biosciences Inc Borsa (ALMR) Ultime notizie
Alamar Biosciences, Inc. (ALMR) stock price, news, quote and history - Yahoo Finance Singapore
Alamar Biosciences, Inc. (ALMR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Among 197 Alzheimer’s patients, 34 of 130 blood markers changed as they received more infusions. - Stock Titan
Alamar Biosciences Study in The Lancet Neurology Finds Distinct Biomarker Responses to Lecanemab in Early Alzheimer’s Disease - Quiver Quantitative
Lancet Neurology Study Using Alamar Biosciences’ Technology - GlobeNewswire
Alamar Biosciences stock rating reiterated at Buy by TD Cowen - Investing.com South Africa
Alamar Biosciences, Inc.(NasdaqGS: ALMR) added to S&P Global BMI Index - marketscreener.com
Alamar Biosciences Shares Soar 15.90% Near 52-Week High Amid Growing Proteomics Analyst and Investor Buzz - International Business Times Australia
Why is Alamar Biosciences stock surging today? By Investing.com - Investing.com South Africa
Alamar Biosciences Soars After High-Profile Conference Buzz - TipRanks
Alamar Biosciences Tumbles As Post‑IPO Hype Fades - TipRanks
Alamar Biosciences, Inc. Common Stock (NASDAQ: ALMR) Stock Price, News & Analysis - Kalkine
Ragusa Robert P. Acquires 5,686 Shares and 25,599 Derivative Securities of Alamar Biosciences - Kalkine Media
Alamar Biosciences (ALMR) director has no reported share holdings - Stock Titan
People in the News at Pillar Biosciences, Devyser, Alamar Biosciences - genomeweb.com
Alamar Biosciences Slides After Conference Hype Fades - TipRanks
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference - The Manila Times
Alamar Biosciences, Inc. Announces Appointment of Robert Ragusa as Director and Member of Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, Effective September 1, 2026 - marketscreener.com
Alamar Biosciences appoints Robert Ragusa to Board and three committees - TradingView
Alamar Biosciences expands proteomics partnership by 86,000 samples - Investing.com Nigeria
Alamar Biosciences (ALMR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Alamar Biosciences: Promising But Expensive Proteomics Growth - Seeking Alpha
Alamar Stock: The Content Flywheel Is More Valuable Than The Instrument (ALMR) - Seeking Alpha
Alamar Biosciences (ALMR) Stock Price Jumps As Margin Gains Meet Loss Pressure - Sahm
Alamar Biosciences (ALMR): Yuling Luo discloses 6.4% beneficial ownership stake - Stock Titan
Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Analysts Offer Insights on NA Companies: Alamar Biosciences, Inc. (ALMR), NIQ Global Intelligence PLC (NIQ) and Amentum Holdings, Inc. (AMTM) - The Globe and Mail
Alamar Biosciences Q2 Results: Revenue Rises 82% To $29.4 Million - scanx.trade
Alamar Biosciences Shares (ALMR) Surge 31% as Consumables Drive Gross Margin Up - TechStock²
Alamar Biosciences (ALMR): Qiming funds report over 10% ownership stake - Stock Titan
Alamar Biosciences launches NULISAseq Immune 340 Panel for profiling - scanx.trade
Stifel raises Alamar Biosciences stock price target on earnings beat By Investing.com - Investing.com Canada
Alamar Biosciences Reports Q2 2026 Financial Results in Form 10-Q Filing - Kalkine Media
ALAMAR BIOSCIENCES INC : STIFEL RAISES TARGET PRICE TO $32 FROM $28 - Bitget
Alamar Biosciences Q2 2026 Earnings Call Transcript - MarketBeat
Alamar Biosciences, Inc. Stock 12‑Month Price Target Raised to $33.4, Implies 19% Upside - TradingView
Alamar Biosciences, Inc. 2Q 2026: Revenue $29.4M, EPS $(0.22) — 10-Q Summary - TradingView
Alamar Biosciences Inc (ALMR) (Q2 2026) Earnings Call Highlights: Revenue Surges 82% on 147% ... - Yahoo Finance Singapore
Alamar Biosciences (ALMR) Stock Trades At A Premium To Its Sales - Yahoo Finance
Alamar Biosciences to report Q2 2026 results on August 10, 2026 - scanx.trade
Form 8K Alamar Biosciences For: 10 August By Investing.com - Investing.com Nigeria
Alamar Biosciences Q2 Earnings Call Highlights - MarketBeat
Alamar Biosciences Q2 revenue surges 82%, led by consumable demand - scanx.trade
Alamar Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Alamar Biosciences posts strong Q2 2026 revenue growth - Investing.com
Alamar Biosciences, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ALMR) 2026-08-10 - Seeking Alpha
ALAMAR BIOSCIENCES ($ALMR) Releases Q2 2026 Earnings - quiverquant.com
Alamar Biosciences Inc Azioni (ALMR) Dati Finanziari
Non sono disponibili dati finanziari per Alamar Biosciences Inc (ALMR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Alamar Biosciences Inc Azioni (ALMR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Naclerio Nicholas | Director |
Apr 20 '26 |
Buy |
17.00 |
235,294 |
3,999,998 |
507,076 |
0.26%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):